

WEST Search History

DATE: Thursday, July 06, 2006

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L30	L29	23
<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L29	L28 and fusion	59
<input type="checkbox"/>	L28	L27 and NS5b	78
<input type="checkbox"/>	L27	L26 and NS5a	80
<input type="checkbox"/>	L26	L25 and NS4	202
<input type="checkbox"/>	L25	L24 and NS3	334
<input type="checkbox"/>	L24	L23 and core	1292
<input type="checkbox"/>	L23	L22 and HCV	2580
<input type="checkbox"/>	L22	polynucleotide	87796
<input type="checkbox"/>	L21	L20 and core	1
<input type="checkbox"/>	L20	L19 and NS2b	1
<input type="checkbox"/>	L19	L18 and NS5a	25
<input type="checkbox"/>	L18	L17 and NS4	50
<input type="checkbox"/>	L17	L16 and NS3	132
<input type="checkbox"/>	L16	L15 and HCV	441
<input type="checkbox"/>	L15	DNA adj vaccine	3997
<i>DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L14	L12	30
<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L13	L12 and fusion	36
<input type="checkbox"/>	L12	L11 and NS5	42
<input type="checkbox"/>	L11	L10 and NS4	49
<input type="checkbox"/>	L10	L9 and NS3	71
<input type="checkbox"/>	L9	L8 and core	106
<input type="checkbox"/>	L8	424/228.1.ICLS.	137
<i>DB=EPAB; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L7	EP-1576125-A2.did.	0
<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L6	L5 and core	1
<input type="checkbox"/>	L5	L4 and NS5	5
<input type="checkbox"/>	L4	L3 and NS4	6
<input type="checkbox"/>	L3	L2 and NS3	13

<input type="checkbox"/>	L2	L1 and HCV	49
<input type="checkbox"/>	L1	Houghton M.in.	130

END OF SEARCH HISTORY

=> HCV (s) fusion
 10846 HCV
 20 HCVS
 10850 HCV
 (HCV OR HCVS)
 257204 FUSION
 9724 FUSIONS
 262422 FUSION
 (FUSION OR FUSIONS)
L1 232 HCV (S) FUSION

=> core and L1
 306959 CORE
 65643 CORES
 339048 CORE
 (CORE OR CORES)
L2 87 CORE AND L1

=> NS3 and L2
 2389 NS3
L3 32 NS3 AND L2

=> NS4 and L3
 641 NS4
L4 15 NS4 AND L3

=> NS5 and L4
 935 NS5
L5 12 NS5 AND L4

=> NS5a and L5
 669 NS5A
L6 2 NS5A AND L5

=> N5b and L5
 6 N5B
L7 0 N5B AND L5

=> polynucleotide and L1
 12982 POLYNUCLEOTIDE
 12926 POLYNUCLEOTIDES
 21414 POLYNUCLEOTIDE
 (POLYNUCLEOTIDE OR POLYNUCLEOTIDES)
L8 9 POLYNUCLEOTIDE AND L1

=> DNA and L1
 779230 DNA
 18599 DNAS
 782128 DNA
 (DNA OR DNAS)
L9 71 DNA AND L1

=> vaccine and L9
 56318 VACCINE
 56827 VACCINES
 70496 VACCINE
 (VACCINE OR VACCINES)
L10 29 VACCINE AND L9

=> DNA adj vaccine
 779230 DNA
 18599 DNAS
 782128 DNA

(DNA OR DNAS)
242 ADJ
56318 VACCINE
56827 VACCINES
70496 VACCINE
(VACCINE OR VACCINES)
L11 0 DNA ADJ VACCINE
(DNA (W) ADJ (W) VACCINE)

=> DNA (s) vaccine
779230 DNA
18599 DNAS
782128 DNA
(DNA OR DNAS)
56318 VACCINE
56827 VACCINES
70496 VACCINE
(VACCINE OR VACCINES)
L12 8639 DNA (S) VACCINE

=> HCV and L12
10846 HCV
20 HCVS
10850 HCV
(HCV OR HCVS)
L13 176 HCV AND L12

=> core and L13
306959 CORE
65643 CORES
339048 CORE
(CORE OR CORES)
L14 80 CORE AND L13

=> NS3 and L14
2389 NS3
L15 16 NS3 AND L14

=> NS4 and L15
641 NS4
L16 8 NS4 AND L15

=> NS5 and L16
935 NS5
L17 7 NS5 AND L16

=> D L6 IBIB ABS 1-2

L5 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:392569 CAPLUS
 DOCUMENT NUMBER: 140:390291
 TITLE: Activation of HCV-specific T cells using fusion protein vaccines comprising HCV NS3, NS4, NS5a, and NS5b polypeptides
 INVENTOR(S): Houghton, Michael; Coates, Steve; Selby, Mark;
 Paliard, Xavier
 PATENT ASSIGNEE(S): Chiron Corporation, USA
 SOURCE: PCT Int. Appl., 136 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039950	A2	20040513	WO 2003-US333610	20031024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2505611	AA	20040513	CA 2003-2505611	20031024
AU 2003287188	A1	20040525	AU 2003-287188	20031024
EP 1576125	A2	20050921	EP 2003-781368	20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-281341	A 20021025
			WO 2003-US33610	W 20031024

AB The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV -specific T cells are activated using fusion protein vaccines comprising HCV NS3, NS4, NS5a, and NS5b polypeptides, polynucleotides encoding such fusion proteins, or polypeptide or polynucleotide compns. containing the individual components of these fusions. The method can be used in model systems to develop HCV-specific immunogenic compns., as well as to immunize a mammal against HCV.

L5 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:41605 CAPLUS
 DOCUMENT NUMBER: 140:110111
 TITLE: HCV fusion proteins with modified NS3 domains for inducing cellular immune response against HCV infection
 INVENTOR(S): Houghton, Michael
 PATENT ASSIGNEE(S): Chiron Corporation, USA
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004005473	A2	20040115	WO 2003-US20996	20030702
WO 2004005473	A3	20040401		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2491508	AA	20040115	CA 2003-2491508	20030702
AU 2003248818	A1	20040123	AU 2003-248818	20030702
EP 1539809	A2	20050615	EP 2003-763172	20030702
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1678630	A	20051005	CN 2003-820719	20030702
JP 2005532064	T2	20051027	JP 2004-519849	20030702
PRIORITY APPLN. INFO.:			US 2002-393694P	P 20020702
			US 2002-394510P	P 20020708
			WO 2003-US20996	W 20030702

AB The invention provides HCV fusion proteins that include a mutated NS3 protease domain, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compns., as well as to immunize a mammal against HCV.